News · Corteva, Inc. (CTVA) · Basic Materials

Corteva rises after JPMorgan upgrade and spin-off context

Session of October 6, 2026 · Published October 7, 2026 · 4 min read

What happened

Corteva (CTVA) rose 12.3% to close at $13.91 on October 6, 2026, as JPMorgan upgraded the stock to overweight and set a $19.00 price target, and as market commentary cited the recent spin-off of its advanced seed business. The upgrade was reported by The Motley Fool and Defense World, and market-data commentary from GuruFocus noted a cluster of sizable early-October moves for the stock.

Closing price over the last 30 trading sessions. On October 6, 2026, CTVA closed at $13.91, up 12.3% on the day and 83.3% lower than 30 sessions earlier.

How big was the move

The stock’s gain on October 6 was 0.5 times a typical daily move for this stock, a level the computed interpretation classifies as an ordinary session. Trading volume ran at 2.1 times its 20-day average, and the stock’s performance was 11.9 percentage points better than the Basic Materials sector median, which rose 0.4% on the day. The S&P 500 rose 0.6% on the session, while over five sessions the index rose 1.9% and the stock had fallen 82.1%.

Each bar is one day's price change; the outlined bar is October 6, 2026. A typical daily move over the past year was 5.5%, so the latest move equals 2.2 times that. Moves outside the dashed lines (about 11.0%) are unusual.

The stock opened 5.6% above the previous close on October 6. Its market value stood at $7.97 billion, and its beta of 0.52 indicates the stock tends to move less than the market.

The technical picture

Technically, the stock traded well below its key moving averages on October 6. The stock was 79.3% below its 20-day moving average, 81.7% below its 50-day moving average and 82.1% below its 200-day moving average. The 50-day average sat below the 200-day average, a sign of a weak longer-term trend.

Closing price over the past year. CTVA ends the period 84.6% below its 52-week high, below its 50-day average ($75.85) and below its 200-day average ($77.62).

Momentum indicators showed extreme weakness. The Relative Strength Index (14 days) was 9, below 30, a level often called oversold. The stock was 84.7% below its 52-week high and had fallen 84.2% over the prior month. Performance was similarly weak over three months and one year, down 83.7% and 78.0%, respectively. Its one-year performance trailed the S&P 500 by 94.5 percentage points, and its 60-day annualized volatility was 376%, the highest reading of the past five years.

Fundamentals and valuation

Over the four quarters through June 30, 2026, Corteva reported revenue of $17.81 billion, which grew 3.7% from a year earlier, and diluted earnings per share of $1.51, which fell 26.4% from a year earlier. Gross margin improved to 48.5% from 45.7% a year earlier, and operating margin rose to 17.1% from 14.7%. Free-cash-flow margin was 3.5% and return on invested capital was 6.2%. The balance sheet showed net debt of 0.8 times EBITDA, and the company’s share count over one year decreased by 1.7%.

Quarterly revenue by period end. The latest quarter brought $6.4B, 1.2% less than the same quarter a year earlier.

Valuation metrics presented a sharp contrast with those fundamentals. The stock traded at 9.2 times trailing earnings, the lowest reading of the past five years versus a five-year median of 39.9 times earnings. Price to forward earnings was 24.6 times expected earnings, and free-cash-flow yield was 7.9%. PromtFinance sector-ranked scores placed Corteva at 99 for Value (Exceptional), 17 for Growth (Very weak), 66 for Quality (Positive) and 11 for Momentum (Very weak). Revisions scored 94 (Exceptional) while Stability scored 32 (Weak).

Taken together, the figures show modest revenue expansion and improved margins alongside sharply lower EPS and very weak price momentum. Trailing earnings point to an inexpensive valuation, while forward expectations leave the stock looking richer on a forward basis.

Earnings and analyst expectations

Corteva’s next report was scheduled for November 3, 2026. The last report, on July 30, 2026, delivered earnings per share of $2.30 against $2.24 expected, 2.7% above estimates, and marked two consecutive quarters beating estimates. The company’s average surprise over the last four reports was 21.0% above estimates, and the typical two-day reaction after recent reports was unchanged.

Diluted earnings per share by quarter. The latest quarter shows $1.73, against $1.92 in the same quarter a year earlier.

Analysts’ consensus price target was $79.50, 471.5% above the closing price on October 6, based on 37 analysts. Sixty-two percent of ratings were Buy and the consensus rating was Buy.

What to watch

November 3, 2026: next earnings report date.
JPMorgan’s $19.00 price target and its October 6 upgrade, reported by The Motley Fool and Defense World.
Corporate context from the spin-off of the advanced seed business completed earlier in October 2026, reported by The Motley Fool.
Share-price metrics: price to trailing earnings at 9.2 times and price to forward earnings at 24.6 times expected earnings.
Technical risk: Relative Strength Index (14 days) at 9 and volatility at 376% annualized over 60 days.

Full CTVA analysis: scores, chart and financials →